The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

PubWeight™: 2.64‹?› | Rank: Top 1%

🔗 View Article (PMID 23770747)

Published in Circulation on June 14, 2013

Authors

Stuart J Connolly1, Lars Wallentin, Michael D Ezekowitz, John Eikelboom, Jonas Oldgren, Paul A Reilly, Martina Brueckmann, Janice Pogue, Marco Alings, John V Amerena, Alvaro Avezum, Iris Baumgartner, Andrzej J Budaj, Jyh-Hong Chen, Antonio L Dans, Harald Darius, Giuseppe Di Pasquale, Jorge Ferreira, Greg C Flaker, Marcus D Flather, Maria Grazia Franzosi, Sergey P Golitsyn, David A Halon, Hein Heidbuchel, Stefan H Hohnloser, Kurt Huber, Petr Jansky, Gabriel Kamensky, Matyas Keltai, Sung Soon Kim, Chu-Pak Lau, Jean-Yves Le Heuzey, Basil S Lewis, Lisheng Liu, John Nanas, Razali Omar, Prem Pais, Knud E Pedersen, Leopoldo S Piegas, Dimitar Raev, Pal J Smith, Mario Talajic, Ru San Tan, Supachai Tanomsup, Lauri Toivonen, Dragos Vinereanu, Denis Xavier, Jun Zhu, Susan Q Wang, Christine O Duffy, Ellison Themeles, Salim Yusuf

Author Affiliations

1: Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.connostu@phri.ca

Associated clinical trials:

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial | NCT00808067

Atrial Fibrillation in Turkey: Epidemiologic Registry-2 (AFTER-2) | NCT02354456

Articles citing this

Long-term prescribing of new oral anticoagulants. Aust Prescr (2016) 1.05

Anticoagulation in atrial fibrillation. BMJ (2014) 0.93

Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol (2014) 0.92

Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. Clin Res Cardiol (2015) 0.91

The new oral anticoagulants in atrial fibrillation: an update. Neth Heart J (2013) 0.91

A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol (2014) 0.89

Continuation of dabigatran therapy in "real-world" practice in Hong Kong. PLoS One (2014) 0.88

The evolution of anticoagulant therapy. Blood Transfus (2015) 0.86

Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace (2016) 0.83

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82

Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther (2014) 0.81

Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: protocol. JMIR Res Protoc (2014) 0.78

A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. Br J Clin Pharmacol (2015) 0.78

New oral anticoagulants in atrial fibrillation forever? Circulation (2013) 0.78

Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro. Mol Pharmacol (2015) 0.77

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care (2016) 0.76

Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. J Stroke (2015) 0.76

Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation. Heart Fail Rev (2014) 0.76

More indications approved and safety news for dabigatran etexilate. Maedica (Buchar) (2014) 0.75

Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Drugs R D (2016) 0.75

Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. BMC Cardiovasc Disord (2017) 0.75

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. Core Evid (2015) 0.75

Anticoagulation in Atrial Fibrillation - Current Concepts. Arrhythm Electrophysiol Rev (2015) 0.75

Anticoagulation therapy: Dabigatran--a RELY-ABLE therapy? Nat Rev Cardiol (2013) 0.75

Recommendations for the use of new oral anticoagulants (NOACs) after TIA or stroke caused by atrial fibrillation (AF), after a consensus conference among Italian neurologists (the Venice group). Neurol Sci (2013) 0.75

[Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants]. Wien Klin Wochenschr (2014) 0.75

Atrial fibrillation: state of the art. Wien Klin Wochenschr (2014) 0.75

Articles by these authors

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Genetics of gene expression and its effect on disease. Nature (2008) 21.35

Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

Mapping the genetic architecture of gene expression in human liver. PLoS Biol (2008) 19.44

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J (2011) 13.10

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

Variations in DNA elucidate molecular networks that cause disease. Nature (2008) 12.04

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Universal definition of myocardial infarction. Circulation (2007) 11.69

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet (2005) 11.40

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14

Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11

Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96

Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69

Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 9.01

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med (2009) 8.73